haloperidol has been researched along with Hyperprolactinaemia in 43 studies
Haloperidol: A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279)
haloperidol : A compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4 and an N-linked p-fluorobutyrophenone moiety.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Fifty-six patients with hyperprolactinemia taking haloperidol were enrolled." | 9.12 | Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial. ( Conley, RR; Jung, DU; Kelly, DL; Liu, KH; Seo, YS; Shim, JC; Shin, JG; Shon, JH, 2007) |
| "Aripiprazole is an investigational agent for treating schizophrenia that has a novel pharmacologic profile." | 9.10 | Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. ( Ali, MW; Carson, WH; Ingenito, GG; Kane, JM; McQuade, RD; Saha, AR; Zimbroff, DL, 2002) |
| " We conducted this 6-month, parallel-group study to prospectively investigate the effects of the dopamine agonist cabergoline on sexual dysfunction in clinically stable patients with schizophrenia (DSM-IV, AP 194) and hyperprolactinemia (PRL > 20 ng/ml for men and PRL > 25 ng/ml for women)." | 7.79 | Effects of cabergoline on hyperprolactinemia, psychopathology, and sexual functioning in schizophrenic patients. ( Arvanitakis, P; Dimopoulou, K; Kalkavoura, CS; Lykouras, L; Michopoulos, I; Theodoropoulou, P; Tzebelikos, E, 2013) |
| "Our results support the previously reported positive impact of atypical antipsychotics, particularly olanzapine, in patients with schizophrenia." | 7.72 | Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol. ( Bitter, I; Boland, J; Dossenbach, M; el Mahfoud Kessaci, M; Erol, A; Hodge, A; O'Halloran, RA; Shaheen, MO; Sunbol, MM, 2004) |
| "The aim of the study was to examine the influence of hyperprolactinemia, induced by haloperidol (HAL) on age related morphology and function changes of epithelial cells in rat prostate lateral lobe." | 7.72 | Aging process of epithelial cells of the rat prostate lateral lobe in experimental hyperprolactinemia induced by haloperidol. ( Laszczyńska, M; Piasecka, M; Słuczanowska-Glabowska, S; Wylot, M, 2004) |
| " A 13-year-old female patient developed hyperprolactinemia with galactorrhea and amenorrhea while receiving thioridazine 300 mg daily." | 7.69 | Attenuation of antipsychotic-induced hyperprolactinemia with clozapine. ( Bunker, MT; Marken, PA; Ruehter, VL; Schneiderhan, ME, 1997) |
| "From December 2004 through March 2008, adult outpatients with a Structured Clinical Interview for DSM-IV Axis I Disorders-Patient Edition diagnosis of schizophrenia or schizoaffective disorder who were taking haloperidol decanoate (n = 40) or fluphenazine decanoate (n = 22) were randomly assigned to stay on current long-acting injectable medication or switch to risperidone microspheres and followed for 6 months under study protocol and an additional 6 months naturalistic follow-up." | 5.16 | Effectiveness of switching from long-acting injectable fluphenazine or haloperidol decanoate to long-acting injectable risperidone microspheres: an open-label, randomized controlled trial. ( Covell, NH; Essock, SM; Jackson, CT; McEvoy, JP; Rojas, IA; Schooler, NR; Stroup, TS, 2012) |
| "Fifty-six patients with hyperprolactinemia taking haloperidol were enrolled." | 5.12 | Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial. ( Conley, RR; Jung, DU; Kelly, DL; Liu, KH; Seo, YS; Shim, JC; Shin, JG; Shon, JH, 2007) |
| "The goal of this study was to compare the effect of risperidone and haloperidol on serum PRL and investigate the relationship between serum PRL levels and clinical response in patients with schizophrenia." | 5.11 | Prolactin levels in male schizophrenic patients treated with risperidone and haloperidol: a double-blind and randomized study. ( Cao, LY; Shen, YC; Wu, GY; Zhang, PY; Zhang, XY; Zhou, DF, 2005) |
| "Aripiprazole is an investigational agent for treating schizophrenia that has a novel pharmacologic profile." | 5.10 | Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. ( Ali, MW; Carson, WH; Ingenito, GG; Kane, JM; McQuade, RD; Saha, AR; Zimbroff, DL, 2002) |
| " We conducted this 6-month, parallel-group study to prospectively investigate the effects of the dopamine agonist cabergoline on sexual dysfunction in clinically stable patients with schizophrenia (DSM-IV, AP 194) and hyperprolactinemia (PRL > 20 ng/ml for men and PRL > 25 ng/ml for women)." | 3.79 | Effects of cabergoline on hyperprolactinemia, psychopathology, and sexual functioning in schizophrenic patients. ( Arvanitakis, P; Dimopoulou, K; Kalkavoura, CS; Lykouras, L; Michopoulos, I; Theodoropoulou, P; Tzebelikos, E, 2013) |
| "In this study, 11 healthy male subjects taking different doses of sulpiride and 24 male patients with DSM-IV-diagnosed schizophrenia taking different antipsychotic drugs (risperidone, olanzapine, haloperidol, and sulpiride) participated." | 3.76 | Positron emission tomography measurement of dopamine D₂ receptor occupancy in the pituitary and cerebral cortex: relation to antipsychotic-induced hyperprolactinemia. ( Arakawa, R; Ito, H; Maeda, J; Okubo, Y; Okumura, M; Suhara, T; Takahashi, H; Takano, A; Takano, H, 2010) |
| " Risperidone had the highest adjusted reporting ratios for hyperprolactinemia (EBGM 34." | 3.73 | Atypical antipsychotics and pituitary tumors: a pharmacovigilance study. ( Doraiswamy, PM; Levine, JG; Szarfman, A; Tonning, JM, 2006) |
| "Factors that influenced the risk of hyperprolactinemia included gender, with females appearing to be more sensitive than males, and drug treatment, with risperidone and conventional antipsychotic agents increasing prolactin more than olanzapine." | 3.72 | Hyperprolactinemia in response to antipsychotic drugs: characterization across comparative clinical trials. ( Gilmore, JA; Halbreich, UM; Kinon, BJ; Liu, H, 2003) |
| "Our results support the previously reported positive impact of atypical antipsychotics, particularly olanzapine, in patients with schizophrenia." | 3.72 | Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol. ( Bitter, I; Boland, J; Dossenbach, M; el Mahfoud Kessaci, M; Erol, A; Hodge, A; O'Halloran, RA; Shaheen, MO; Sunbol, MM, 2004) |
| "The aim of the study was to examine the influence of hyperprolactinemia, induced by haloperidol (HAL) on age related morphology and function changes of epithelial cells in rat prostate lateral lobe." | 3.72 | Aging process of epithelial cells of the rat prostate lateral lobe in experimental hyperprolactinemia induced by haloperidol. ( Laszczyńska, M; Piasecka, M; Słuczanowska-Glabowska, S; Wylot, M, 2004) |
| ") with haloperidol (HAL), a dopamine receptor antagonist for 6 or 9 months to produce hyperprolactinemia." | 3.70 | Effects of chronic hyperprolactinemia on tuberoinfundibular dopaminergic neurons. ( Arbogast, L; MohanKumar, PS; MohanKumar, SM; Quadri, SK; Voogt, JL, 1998) |
| "The purpose of this study was to determine the effects of acute hypoprolactinemia on tuberoinfundibular dopamine (DA) neurons using a rabbit anti-rat prolactin antiserum (PRL-AB) to immunoneutralize circulating prolactin under basal conditions and at various times after haloperidol-induced hyperprolactinemia." | 3.70 | Prolactin regulation of tuberoinfundibular dopaminergic neurons: immunoneutralization studies. ( Fleckenstein, AE; Hentschel, K; Lawson, DM; Lookingland, KJ; Moore, KE; Toney, TW, 2000) |
| " A 13-year-old female patient developed hyperprolactinemia with galactorrhea and amenorrhea while receiving thioridazine 300 mg daily." | 3.69 | Attenuation of antipsychotic-induced hyperprolactinemia with clozapine. ( Bunker, MT; Marken, PA; Ruehter, VL; Schneiderhan, ME, 1997) |
| " The blood PRL concentration of female rats was altered by 1) three daily injections of haloperidol (chronic hyperprolactinemia) with or without bromocriptine administration 4 h before death, 2) bromocriptine alone for 4 h (acute hypoprolactinemia), and 3) a single vascular injection of ovine PRL (acute hyperprolactinemia)." | 3.68 | Prolactin enhancement of its own uptake at the choroid plexus. ( Mangurian, LP; Posner, BI; Walsh, RJ, 1992) |
| " Hyperprolactinaemia produced by treatment with either dopamine antagonists (domperidone or haloperidol) or ovine prolactin was also associated with an impairment of the OT stress response in intact females, whereas domperidone treatment failed to modify the response in ovariectomized (OVX) rats." | 3.67 | Oxytocin responses to stress in lactating and hyperprolactinaemic rats. ( Carter, DA; Lightman, SL, 1987) |
| "Risperidone (3 microM) was found to slow the rate of activation." | 1.31 | Characterization of inhibition by risperidone of the inwardly rectifying K(+) current in pituitary GH(3) cells. ( Chiang, HT; Jan, CR; Li, HF; Wu, SN, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (6.98) | 18.7374 |
| 1990's | 8 (18.60) | 18.2507 |
| 2000's | 21 (48.84) | 29.6817 |
| 2010's | 10 (23.26) | 24.3611 |
| 2020's | 1 (2.33) | 2.80 |
| Authors | Studies |
|---|---|
| Lange, JH | 1 |
| Reinders, JH | 1 |
| Tolboom, JT | 1 |
| Glennon, JC | 1 |
| Coolen, HK | 1 |
| Kruse, CG | 1 |
| Gao, L | 1 |
| Hao, C | 1 |
| Chen, J | 1 |
| Ma, R | 1 |
| Zheng, L | 1 |
| Wu, Q | 1 |
| Liu, X | 1 |
| Liu, BF | 1 |
| Zhang, G | 1 |
| Chen, Y | 1 |
| Jin, J | 1 |
| Kalkavoura, CS | 1 |
| Michopoulos, I | 1 |
| Arvanitakis, P | 1 |
| Theodoropoulou, P | 1 |
| Dimopoulou, K | 1 |
| Tzebelikos, E | 1 |
| Lykouras, L | 1 |
| Wei, Y | 1 |
| Wang, X | 1 |
| Yu, Z | 1 |
| Zhou, W | 1 |
| Wang, L | 1 |
| Qin, F | 1 |
| Wang, C | 1 |
| Hou, L | 1 |
| Potanin, SS | 1 |
| Burminskiy, DS | 1 |
| Morozova, MA | 1 |
| Platova, AI | 1 |
| Baymeeva, NV | 1 |
| Miroshnichenko, II | 1 |
| Madhusoodanan, S | 1 |
| Steinberg, LR | 1 |
| Coleman, A | 1 |
| Bavli, S | 1 |
| Kim, E | 1 |
| Correll, CU | 1 |
| Mao, L | 1 |
| Starr, HL | 1 |
| Alphs, L | 1 |
| Arakawa, R | 1 |
| Okumura, M | 1 |
| Ito, H | 1 |
| Takano, A | 1 |
| Takahashi, H | 1 |
| Takano, H | 1 |
| Maeda, J | 1 |
| Okubo, Y | 1 |
| Suhara, T | 1 |
| Kunimatsu, T | 1 |
| Kimura, J | 1 |
| Funabashi, H | 1 |
| Inoue, T | 1 |
| Seki, T | 1 |
| Rung, JP | 1 |
| Rung, E | 1 |
| Johansson, AM | 1 |
| Svensson, K | 1 |
| Carlsson, A | 1 |
| Carlsson, ML | 1 |
| Covell, NH | 1 |
| McEvoy, JP | 1 |
| Schooler, NR | 1 |
| Stroup, TS | 1 |
| Jackson, CT | 1 |
| Rojas, IA | 1 |
| Essock, SM | 1 |
| Wang, D | 1 |
| Wong, HK | 1 |
| Zhang, L | 1 |
| McAlonan, GM | 1 |
| Wang, XM | 1 |
| Sze, SC | 1 |
| Feng, YB | 1 |
| Zhang, ZJ | 1 |
| Kane, JM | 1 |
| Carson, WH | 1 |
| Saha, AR | 1 |
| McQuade, RD | 1 |
| Ingenito, GG | 1 |
| Zimbroff, DL | 1 |
| Ali, MW | 1 |
| Kinon, BJ | 1 |
| Gilmore, JA | 1 |
| Liu, H | 1 |
| Halbreich, UM | 1 |
| Gupta, S | 1 |
| Dossenbach, M | 1 |
| Erol, A | 1 |
| el Mahfoud Kessaci, M | 1 |
| Shaheen, MO | 1 |
| Sunbol, MM | 1 |
| Boland, J | 1 |
| Hodge, A | 1 |
| O'Halloran, RA | 1 |
| Bitter, I | 1 |
| Zhang, XY | 1 |
| Zhou, DF | 1 |
| Cao, LY | 1 |
| Zhang, PY | 1 |
| Wu, GY | 1 |
| Shen, YC | 1 |
| Wylot, M | 1 |
| Laszczyńska, M | 1 |
| Słuczanowska-Glabowska, S | 1 |
| Piasecka, M | 1 |
| Schooler, N | 1 |
| Rabinowitz, J | 1 |
| Davidson, M | 1 |
| Emsley, R | 1 |
| Harvey, PD | 1 |
| Kopala, L | 1 |
| McGorry, PD | 1 |
| Van Hove, I | 1 |
| Eerdekens, M | 1 |
| Swyzen, W | 1 |
| De Smedt, G | 1 |
| Jung, DU | 2 |
| Seo, YS | 2 |
| Park, JH | 1 |
| Jeong, CY | 1 |
| Conley, RR | 2 |
| Kelly, DL | 2 |
| Shim, JC | 2 |
| Szarfman, A | 1 |
| Tonning, JM | 1 |
| Levine, JG | 1 |
| Doraiswamy, PM | 1 |
| Kessler, RM | 1 |
| Shin, JG | 1 |
| Liu, KH | 1 |
| Shon, JH | 1 |
| Lorenz, RA | 1 |
| Weinstein, B | 1 |
| Konopelska, S | 1 |
| Quinkler, M | 1 |
| Strasburger, CJ | 1 |
| Ventz, M | 1 |
| Hazra, M | 1 |
| Mamo, DC | 1 |
| Remington, G | 2 |
| Bunker, MT | 1 |
| Marken, PA | 1 |
| Schneiderhan, ME | 1 |
| Ruehter, VL | 1 |
| Crawford, AM | 1 |
| Beasley, CM | 1 |
| Tollefson, GD | 1 |
| MohanKumar, PS | 1 |
| MohanKumar, SM | 1 |
| Arbogast, L | 1 |
| Quadri, SK | 1 |
| Voogt, JL | 2 |
| Spitzer, M | 1 |
| Sajjad, R | 1 |
| Benjamin, F | 1 |
| Oliveira, MC | 1 |
| Messinger, HP | 1 |
| Tannhauser, M | 1 |
| Barbosa-Coutinho, L | 1 |
| Hentschel, K | 1 |
| Fleckenstein, AE | 1 |
| Toney, TW | 1 |
| Lawson, DM | 1 |
| Moore, KE | 1 |
| Lookingland, KJ | 1 |
| Kapur, S | 1 |
| Zipursky, R | 1 |
| Jones, C | 1 |
| Houle, S | 1 |
| Wu, SN | 1 |
| Jan, CR | 1 |
| Li, HF | 1 |
| Chiang, HT | 1 |
| Pi, X | 1 |
| Mihara, K | 1 |
| Suzuki, A | 1 |
| Kondo, T | 1 |
| Yasui-Furukori, N | 1 |
| Ono, S | 1 |
| Otani, K | 1 |
| Kaneko, S | 1 |
| Inoue, Y | 1 |
| Liégeois, JF | 1 |
| Bruhwyler, J | 1 |
| Hendrick, JC | 1 |
| Delarge, J | 1 |
| Legros, JJ | 1 |
| Damas, J | 1 |
| Mangurian, LP | 1 |
| Walsh, RJ | 1 |
| Posner, BI | 1 |
| Becú-Villalobos, D | 1 |
| Thyssen, SM | 1 |
| Rey, EB | 1 |
| Lux-Lantos, V | 1 |
| Libertun, C | 1 |
| LaFleur, P | 1 |
| Van Norman, J | 1 |
| Nader, S | 1 |
| Shapiro, L | 1 |
| Peabody, CA | 1 |
| Arita, J | 1 |
| Kimura, F | 1 |
| Carter, DA | 1 |
| Lightman, SL | 1 |
| Benfenati, F | 1 |
| Ferretti, C | 1 |
| Cimino, M | 1 |
| Vantini, G | 1 |
| Lipartiti, M | 1 |
| Muccioli, G | 1 |
| Di Carlo, R | 1 |
| Algeri, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized Trial to Compare the Efficiency and Side Effect Between Olanzapine and Long-acting Paliperidone Palmitate Injection in Schizophrenia[NCT02918825] | 100 participants (Actual) | Interventional | 2016-09-01 | Completed | |||
| Effectiveness of Switching Antipsychotic Medications[NCT00044655] | Phase 4 | 219 participants (Actual) | Interventional | 2001-07-31 | Completed | ||
| Aripiprazole, Abilify Maintena Collaborative Clinical Protocol[NCT02717130] | 9 participants (Actual) | Interventional | 2016-06-08 | Terminated (stopped due to The study was terminated due to lack of enrollment.) | |||
| Risk of Breakthrough Symptoms On Antipsychotic Maintenance Medication When Remitted Patients Are Treated With Long-Acting Injectable Medications[NCT05473741] | 180 participants (Anticipated) | Observational | 2023-01-09 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00044655)
Timeframe: Measured at Six Months
| Intervention | participants (Number) |
|---|---|
| Stay | 11 |
| Switch | 23 |
3 reviews available for haloperidol and Hyperprolactinaemia
| Article | Year |
|---|---|
Hyperprolactinemia Secondary to Pituitary Microadenoma Versus Haloperidol- A Diagnostic Enigma. A Case Report and Brief Review.
Topics: Adenoma; Antipsychotic Agents; Diagnosis, Differential; Haloperidol; Humans; Hyperprolactinemia; Mal | 2017 |
Safety in treating bipolar disorder.
Topics: Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Clozapine; Diabetes Melli | 2003 |
Difficulties in the medical treatment of prolactinoma in a patient with schizophrenia--a case report with a review of the literature.
Topics: Adult; Antipsychotic Agents; Bromocriptine; Clozapine; Dopamine Agonists; Dopamine Antagonists; Drug | 2008 |
8 trials available for haloperidol and Hyperprolactinaemia
| Article | Year |
|---|---|
Once-monthly paliperidone palmitate compared with conventional and atypical daily oral antipsychotic treatment in patients with schizophrenia.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Benzodiazep | 2016 |
Effectiveness of switching from long-acting injectable fluphenazine or haloperidol decanoate to long-acting injectable risperidone microspheres: an open-label, randomized controlled trial.
Topics: Antipsychotic Agents; Connecticut; Delayed-Action Preparations; Drug Substitution; Female; Fluphenaz | 2012 |
Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder.
Topics: Acute Disease; Adult; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Body Weight; Doubl | 2002 |
Prolactin levels in male schizophrenic patients treated with risperidone and haloperidol: a double-blind and randomized study.
Topics: Adult; Antipsychotic Agents; Double-Blind Method; Female; Haloperidol; Humans; Hyperprolactinemia; M | 2005 |
Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial.
Topics: Adult; Antipsychotic Agents; Double-Blind Method; Drug Administration Schedule; Dyskinesia, Drug-Ind | 2005 |
Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Brief Psychiatric Rating Scale; Dopamine Anta | 2007 |
The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chi-Square Distribution; Cross-Sectional Studies; Dopa | 1997 |
Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Basal Ganglia Diseases; Carbon Radioisotopes; Corpus Striat | 2000 |
32 other studies available for haloperidol and Hyperprolactinaemia
| Article | Year |
|---|---|
Principal component analysis differentiates the receptor binding profiles of three antipsychotic drug candidates from current antipsychotic drugs.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Benzoxazines; Biogenic Monoamines; Humans; Hyperprolac | 2007 |
Discovery of a new class of multi-target heterocycle piperidine derivatives as potential antipsychotics with pro-cognitive effect.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Cognition; Dopamine; Drug Design; Humans; Hyperprol | 2021 |
Effects of cabergoline on hyperprolactinemia, psychopathology, and sexual functioning in schizophrenic patients.
Topics: Adult; Amisulpride; Antipsychotic Agents; Cabergoline; Diagnostic and Statistical Manual of Mental D | 2013 |
Efficacy and Mechanism of Action of Yiru Tiaojing Granule Against Hyperprolactinemia In Vitro and In Vivo.
Topics: Animals; Brain; Bromocriptine; Cell Line; Cyclic AMP; Cyclic AMP-Dependent Protein Kinases; Disease | 2015 |
[Plasma levels of antipsychotics and the severity of side-effects in the treatment of schizophrenia exacerbation].
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Blood Glucose; Clozapi | 2015 |
Positron emission tomography measurement of dopamine D₂ receptor occupancy in the pituitary and cerebral cortex: relation to antipsychotic-induced hyperprolactinemia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Carbon Radioisotopes; Cerebellar Cortex; Cerebral Cort | 2010 |
The antipsychotics haloperidol and chlorpromazine increase bone metabolism and induce osteopenia in female rats.
Topics: Amino Acids; Animals; Antipsychotic Agents; Bone and Bones; Bone Density; Bone Diseases, Metabolic; | 2010 |
Effects of the dopamine stabilizers (S)-(-)-OSU6162 and ACR16 on prolactin secretion in drug-naive and monoamine-depleted rats.
Topics: Animals; Aripiprazole; Dopamine; Dopamine Agonists; Dopamine Antagonists; Dopamine D2 Receptor Antag | 2011 |
Not only dopamine D2 receptors involved in Peony-Glycyrrhiza Decoction, an herbal preparation against antipsychotic-associated hyperprolactinemia.
Topics: Animals; Bromocriptine; Cell Line; Disease Models, Animal; Dopamine; Dopamine D2 Receptor Antagonist | 2012 |
Hyperprolactinemia in response to antipsychotic drugs: characterization across comparative clinical trials.
Topics: Adult; Age Factors; Aged; Antipsychotic Agents; Benzodiazepines; Clinical Trials as Topic; Estrogens | 2003 |
Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Cognition Disorders; Diagnostic and Statistical Manual | 2004 |
Aging process of epithelial cells of the rat prostate lateral lobe in experimental hyperprolactinemia induced by haloperidol.
Topics: Aging; Animals; Disease Models, Animal; Epithelial Cells; Haloperidol; Hyperprolactinemia; Male; Pro | 2004 |
The prevalence of hyperprolactinemia after long-term haloperidol use in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Chronic Disease; Drug Administration Schedule; Female; Haloperidol; Hum | 2005 |
Atypical antipsychotics and pituitary tumors: a pharmacovigilance study.
Topics: Adolescent; Adverse Drug Reaction Reporting Systems; Amenorrhea; Antipsychotic Agents; Aripiprazole; | 2006 |
Aripiprazole: what is the role of dopamine D(2) receptor partial agonism?
Topics: Antipsychotic Agents; Aripiprazole; Drug Therapy, Combination; Haloperidol; Humans; Hyperprolactinem | 2007 |
Resolution of haloperidol-induced hyperprolactinemia with aripiprazole.
Topics: Adult; Antimanic Agents; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Clonazepam; Dose-Resp | 2007 |
Adjunctive versus monotherapeutic treatment for schizophrenia: addressing antipsychotic side effects.
Topics: Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Dose-Response Relationship, Drug; Drug C | 2008 |
Attenuation of antipsychotic-induced hyperprolactinemia with clozapine.
Topics: Adolescent; Amenorrhea; Antipsychotic Agents; Bromocriptine; Clozapine; Female; Fluphenazine; Galact | 1997 |
Effects of chronic hyperprolactinemia on tuberoinfundibular dopaminergic neurons.
Topics: Animals; Arcuate Nucleus of Hypothalamus; Body Weight; Dopamine; Dopamine Antagonists; Estrus; Femal | 1998 |
Pattern of development of hyperprolactinemia after initiation of haloperidol therapy.
Topics: Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Female; Haloperidol; Humans; Hyperprolactinemi | 1998 |
Chronic effect of antidopaminergic drugs or estrogen on male wistar rat lactotrophs and somatotrophs.
Topics: Animals; Dopamine Antagonists; Estrogens; Fluphenazine; Growth Hormone; Haloperidol; Hyperprolactine | 1999 |
Prolactin regulation of tuberoinfundibular dopaminergic neurons: immunoneutralization studies.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Arcuate Nucleus of Hypothalamus; Dopamine; Dopamine Antagon | 2000 |
Characterization of inhibition by risperidone of the inwardly rectifying K(+) current in pituitary GH(3) cells.
Topics: Action Potentials; Animals; Antipsychotic Agents; Calcium Channels; Haloperidol; Hyperprolactinemia; | 2000 |
Mechanisms for suckling-induced changes in expression of prolactin receptor in the hypothalamus of the lactating rat.
Topics: Animals; Animals, Suckling; Bromocriptine; Dopamine Agonists; Dopamine Antagonists; Female; Haloperi | 2001 |
Relationship between Taq1 A dopamine D2 receptor (DRD2) polymorphism and prolactin response to bromperidol.
Topics: Adult; Alleles; Deoxyribonucleases, Type II Site-Specific; Dopamine Antagonists; Female; Genotype; H | 2001 |
Minimal effects of JL 13, a pyridobenzoxazepine derivative with an antipsychotic potential, on circulating prolactin levels in male rats.
Topics: Animals; Antipsychotic Agents; Clozapine; Dopamine D2 Receptor Antagonists; Dose-Response Relationsh | 2002 |
Prolactin enhancement of its own uptake at the choroid plexus.
Topics: Animals; Autoradiography; Biological Transport; Bromocriptine; Choroid Plexus; Electrophoresis, Poly | 1992 |
Octopamine and phenylethylamine inhibit prolactin secretion both in vivo and in vitro.
Topics: Analysis of Variance; Animals; Dopamine; Dose-Response Relationship, Drug; Drug Synergism; Haloperid | 1992 |
Association of high prolactin levels and neuroleptics immediately postpartum.
Topics: Adult; Female; Haloperidol; Humans; Hyperplasia; Hyperprolactinemia; Pituitary Gland; Prolactin; Pue | 1990 |
Characterization of in vitro dopamine synthesis in the median eminence of rats with haloperidol-induced hyperprolactinemia and bromocriptine-induced hypoprolactinemia.
Topics: Animals; Bromocriptine; Calcium; Cyclic AMP; Dihydroxyphenylalanine; Dopamine; Female; Haloperidol; | 1986 |
Oxytocin responses to stress in lactating and hyperprolactinaemic rats.
Topics: Animals; Domperidone; Estradiol; Female; Haloperidol; Hyperprolactinemia; Lactation; Oxytocin; Pregn | 1987 |
Effects of sustained hyperprolactinemia induced by chronic treatment with domperidone on central dopaminergic systems in the rat.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striatum; Domperidone; Dopamine; Drug Administration | 1986 |